AVDL Quote, Financials, Valuation and Earnings

Iterum Therapeutics PLC has a net margin of -5.25% compared to Avadel Pharmaceuticals PLC's net margin of --. Avadel Pharmaceuticals PLC's return on equity of -86.15% beat Iterum Therapeutics PLC's return on equity of --.

Avadel Pharmaceuticals PLC has a consensus price target of --, signalling upside risk potential of 129.78%. On the other hand Iterum Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 321.35%. Given that Iterum Therapeutics PLC has higher upside potential than Avadel Pharmaceuticals PLC, analysts believe Iterum Therapeutics PLC is more attractive than Avadel Pharmaceuticals PLC.

Avadel Pharmaceuticals PLC has a beta of 1.317, which suggesting that the stock is 31.685% more volatile than S&P 500. In comparison Iterum Therapeutics PLC has a beta of 2.404, suggesting its more volatile than the S&P 500 by 140.42%.

Avadel Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avadel Pharmaceuticals PLC pays -- of its earnings as a dividend. Iterum Therapeutics PLC pays out -- of its earnings as a dividend.

Avadel Pharmaceuticals PLC quarterly revenues are $50M, which are larger than Iterum Therapeutics PLC quarterly revenues of --. Avadel Pharmaceuticals PLC's net income of -$2.6M is higher than Iterum Therapeutics PLC's net income of -$7.1M. Notably, Avadel Pharmaceuticals PLC's price-to-earnings ratio is -- while Iterum Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avadel Pharmaceuticals PLC is 6.86x versus 33.98x for Iterum Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals PLC has a net margin of -5.25% compared to Avadel Pharmaceuticals PLC's net margin of 20.39%. Avadel Pharmaceuticals PLC's return on equity of -86.15% beat Jazz Pharmaceuticals PLC's return on equity of 12.28%.

Avadel Pharmaceuticals PLC has a consensus price target of --, signalling upside risk potential of 129.78%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $181.05 which suggests that it could grow by 45.72%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Jazz Pharmaceuticals PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Jazz Pharmaceuticals PLC.

Avadel Pharmaceuticals PLC has a beta of 1.317, which suggesting that the stock is 31.685% more volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.191%.

Avadel Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avadel Pharmaceuticals PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Avadel Pharmaceuticals PLC quarterly revenues are $50M, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Avadel Pharmaceuticals PLC's net income of -$2.6M is lower than Jazz Pharmaceuticals PLC's net income of $215.1M. Notably, Avadel Pharmaceuticals PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 17.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avadel Pharmaceuticals PLC is 6.86x versus 2.06x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic PLC has a net margin of -5.25% compared to Avadel Pharmaceuticals PLC's net margin of 15.11%. Avadel Pharmaceuticals PLC's return on equity of -86.15% beat Medtronic PLC's return on equity of 8.54%.

Avadel Pharmaceuticals PLC has a consensus price target of --, signalling upside risk potential of 129.78%. On the other hand Medtronic PLC has an analysts' consensus of $96.00 which suggests that it could grow by 17.94%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Medtronic PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Medtronic PLC.

Avadel Pharmaceuticals PLC has a beta of 1.317, which suggesting that the stock is 31.685% more volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.820, suggesting its less volatile than the S&P 500 by 17.999%.

Avadel Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.42% to investors and pays a quarterly dividend of $0.70 per share. Avadel Pharmaceuticals PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 99.73% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Avadel Pharmaceuticals PLC quarterly revenues are $50M, which are smaller than Medtronic PLC quarterly revenues of $8.4B. Avadel Pharmaceuticals PLC's net income of -$2.6M is lower than Medtronic PLC's net income of $1.3B. Notably, Avadel Pharmaceuticals PLC's price-to-earnings ratio is -- while Medtronic PLC's PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avadel Pharmaceuticals PLC is 6.86x versus 3.23x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co PLC has a net margin of -5.25% compared to Avadel Pharmaceuticals PLC's net margin of -1.93%. Avadel Pharmaceuticals PLC's return on equity of -86.15% beat Perrigo Co PLC's return on equity of -3.43%.

Avadel Pharmaceuticals PLC has a consensus price target of --, signalling upside risk potential of 129.78%. On the other hand Perrigo Co PLC has an analysts' consensus of -- which suggests that it could grow by 39.52%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Perrigo Co PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Perrigo Co PLC.

Avadel Pharmaceuticals PLC has a beta of 1.317, which suggesting that the stock is 31.685% more volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.517, suggesting its less volatile than the S&P 500 by 48.32%.

Avadel Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.3% to investors and pays a quarterly dividend of $0.28 per share. Avadel Pharmaceuticals PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -1178.74% of its earnings as a dividend.

Avadel Pharmaceuticals PLC quarterly revenues are $50M, which are smaller than Perrigo Co PLC quarterly revenues of $1.1B. Avadel Pharmaceuticals PLC's net income of -$2.6M is higher than Perrigo Co PLC's net income of -$21M. Notably, Avadel Pharmaceuticals PLC's price-to-earnings ratio is -- while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avadel Pharmaceuticals PLC is 6.86x versus 0.80x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.